A recent study reports a lower risk of Parkinson’s disease in older adults with osteoporosis who were treated with romosozumab compared to those treated with two parathyroid hormone receptor agonists—teriparatide and abaloparatide—suggesting that Wnt/catenin pathway activation via the blocking of sclerostin may reduce the risk of PD progression from the prodromal to the motor stage [60]. This evidence concerns the gene SOST and osteoporosis.